Integra Lifesciences Holdings (IART) Interest Expenses (2009 - 2026)

Integra Lifesciences Holdings (IART) has 18 years of Interest Expenses data on file, last reported at $91.8 million in Q1 2026.

• For the quarter ending Q1 2026, Interest Expenses fell 79.1% year-over-year to $91.8 million; the trailing twelve-month figure through Mar 2026 stood at $91.8 million (down 79.1% YoY), and the FY2025 full-year result was $97.7 million, up 38.32% from the prior year.
• Interest Expenses improved to $91.8 million in Q1 2026, from $5.4 million in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $511.8 million in Q3 2024 to a low of $5.4 million in Q4 2025.
• A 5-year average of $217.2 million and a median of $96.9 million in 2024 frame the typical range for Interest Expenses.
• Across the five-year window, Interest Expenses soared 543.24% in 2022 and plunged 84.34% in 2023, its largest moves.
• Tracing IART's Interest Expenses over 5 years: stood at $36.8 million in 2022, then tumbled by 62.62% to $13.8 million in 2023, then slumped by 57.33% to $5.9 million in 2024, then retreated by 7.55% to $5.4 million in 2025, then soared by 1592.48% to $91.8 million in 2026.
• Business Quant data shows IART's Interest Expenses at $91.8 million in Q1 2026, $5.4 million in Q4 2025, and $262.1 million in Q3 2025.